img

Global Insulin Biosimilars Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Insulin Biosimilars Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Biosimilar insulin is likely to enter the insulin landscape as patents for major branded insulin products start to expire in the next few years. Biosimilar insulin has the potential to reduce diabetes treatment costs, increase the accessibility of insulin treatment, and expand the number of insulin brands available for those with diabetes.
Insulin Biosimilars report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Insulin Biosimilars market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Type I Diabetes and Type II Diabetes are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Insulin Biosimilars industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Insulin Biosimilars key manufacturers include Sanofi S.A., Boehringer Ingelheim, Eli Lilly & Co., Novo Nordisk A/S, Biocon, Geropharm, Wockhardt, Gan&Lee Pharmaceuticals and The United Laboratories International, etc. Sanofi S.A., Boehringer Ingelheim, Eli Lilly & Co. are top 3 players and held % sales share in total in 2022.
Insulin Biosimilars can be divided into Rapid-Acting Biosimilars, Long-Acting Biosimilars and Premixed Biosimilars,, etc. Rapid-Acting Biosimilars is the mainstream product in the market, accounting for % sales share globally in 2022.
Insulin Biosimilars is widely used in various fields, such as Type I Diabetes and Type II Diabetes, etc. Type I Diabetes provides greatest supports to the Insulin Biosimilars industry development. In 2022, global % sales of Insulin Biosimilars went into Type I Diabetes filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Insulin Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Sanofi S.A.
Boehringer Ingelheim
Eli Lilly & Co.
Novo Nordisk A/S
Biocon
Geropharm
Wockhardt
Gan&Lee Pharmaceuticals
The United Laboratories International
Tonghua Dongbao Pharmaceutical
Segment by Type
Rapid-Acting Biosimilars
Long-Acting Biosimilars
Premixed Biosimilars

Segment by Application


Type I Diabetes
Type II Diabetes

Segment by Region


North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Insulin Biosimilars market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Insulin Biosimilars, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Insulin Biosimilars industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Insulin Biosimilars in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Insulin Biosimilars introduction, etc. Insulin Biosimilars Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Insulin Biosimilars market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Insulin Biosimilars Market Overview
1.1 Insulin Biosimilars Product Overview
1.2 Insulin Biosimilars Market Segment by Type
1.2.1 Rapid-Acting Biosimilars
1.2.2 Long-Acting Biosimilars
1.2.3 Premixed Biosimilars
1.3 Global Insulin Biosimilars Market Size by Type
1.3.1 Global Insulin Biosimilars Market Size Overview by Type (2024-2034)
1.3.2 Global Insulin Biosimilars Historic Market Size Review by Type (2024-2024)
1.3.3 Global Insulin Biosimilars Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Insulin Biosimilars Sales Breakdown by Type (2024-2024)
1.4.2 Europe Insulin Biosimilars Sales Breakdown by Type (2024-2024)
1.4.3 Asia-Pacific Insulin Biosimilars Sales Breakdown by Type (2024-2024)
1.4.4 Latin America Insulin Biosimilars Sales Breakdown by Type (2024-2024)
1.4.5 Middle East and Africa Insulin Biosimilars Sales Breakdown by Type (2024-2024)
2 Global Insulin Biosimilars Market Competition by Company
2.1 Global Top Players by Insulin Biosimilars Sales (2024-2024)
2.2 Global Top Players by Insulin Biosimilars Revenue (2024-2024)
2.3 Global Top Players by Insulin Biosimilars Price (2024-2024)
2.4 Global Top Manufacturers Insulin Biosimilars Manufacturing Base Distribution, Sales Area, Product Type
2.5 Insulin Biosimilars Market Competitive Situation and Trends
2.5.1 Insulin Biosimilars Market Concentration Rate (2024-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Insulin Biosimilars Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Insulin Biosimilars as of 2022)
2.7 Date of Key Manufacturers Enter into Insulin Biosimilars Market
2.8 Key Manufacturers Insulin Biosimilars Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Insulin Biosimilars Status and Outlook by Region
3.1 Global Insulin Biosimilars Market Size and CAGR by Region: 2024 VS 2022 VS 2034
3.2 Global Insulin Biosimilars Historic Market Size by Region
3.2.1 Global Insulin Biosimilars Sales in Volume by Region (2024-2024)
3.2.2 Global Insulin Biosimilars Sales in Value by Region (2024-2024)
3.2.3 Global Insulin Biosimilars Sales (Volume & Value) Price and Gross Margin (2024-2024)
3.3 Global Insulin Biosimilars Forecasted Market Size by Region
3.3.1 Global Insulin Biosimilars Sales in Volume by Region (2024-2034)
3.3.2 Global Insulin Biosimilars Sales in Value by Region (2024-2034)
3.3.3 Global Insulin Biosimilars Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Insulin Biosimilars by Application
4.1 Insulin Biosimilars Market Segment by Application
4.1.1 Type I Diabetes
4.1.2 Type II Diabetes
4.2 Global Insulin Biosimilars Market Size by Application
4.2.1 Global Insulin Biosimilars Market Size Overview by Application (2024-2034)
4.2.2 Global Insulin Biosimilars Historic Market Size Review by Application (2024-2024)
4.2.3 Global Insulin Biosimilars Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Insulin Biosimilars Sales Breakdown by Application (2024-2024)
4.3.2 Europe Insulin Biosimilars Sales Breakdown by Application (2024-2024)
4.3.3 Asia-Pacific Insulin Biosimilars Sales Breakdown by Application (2024-2024)
4.3.4 Latin America Insulin Biosimilars Sales Breakdown by Application (2024-2024)
4.3.5 Middle East and Africa Insulin Biosimilars Sales Breakdown by Application (2024-2024)
5 North America Insulin Biosimilars by Country
5.1 North America Insulin Biosimilars Historic Market Size by Country
5.1.1 North America Insulin Biosimilars Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
5.1.2 North America Insulin Biosimilars Sales in Volume by Country (2024-2024)
5.1.3 North America Insulin Biosimilars Sales in Value by Country (2024-2024)
5.2 North America Insulin Biosimilars Forecasted Market Size by Country
5.2.1 North America Insulin Biosimilars Sales in Volume by Country (2024-2034)
5.2.2 North America Insulin Biosimilars Sales in Value by Country (2024-2034)
6 Europe Insulin Biosimilars by Country
6.1 Europe Insulin Biosimilars Historic Market Size by Country
6.1.1 Europe Insulin Biosimilars Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
6.1.2 Europe Insulin Biosimilars Sales in Volume by Country (2024-2024)
6.1.3 Europe Insulin Biosimilars Sales in Value by Country (2024-2024)
6.2 Europe Insulin Biosimilars Forecasted Market Size by Country
6.2.1 Europe Insulin Biosimilars Sales in Volume by Country (2024-2034)
6.2.2 Europe Insulin Biosimilars Sales in Value by Country (2024-2034)
7 Asia-Pacific Insulin Biosimilars by Region
7.1 Asia-Pacific Insulin Biosimilars Historic Market Size by Region
7.1.1 Asia-Pacific Insulin Biosimilars Market Size Growth Rate (CAGR) by Region: 2024 VS 2022 VS 2034
7.1.2 Asia-Pacific Insulin Biosimilars Sales in Volume by Region (2024-2024)
7.1.3 Asia-Pacific Insulin Biosimilars Sales in Value by Region (2024-2024)
7.2 Asia-Pacific Insulin Biosimilars Forecasted Market Size by Region
7.2.1 Asia-Pacific Insulin Biosimilars Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Insulin Biosimilars Sales in Value by Region (2024-2034)
8 Latin America Insulin Biosimilars by Country
8.1 Latin America Insulin Biosimilars Historic Market Size by Country
8.1.1 Latin America Insulin Biosimilars Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
8.1.2 Latin America Insulin Biosimilars Sales in Volume by Country (2024-2024)
8.1.3 Latin America Insulin Biosimilars Sales in Value by Country (2024-2024)
8.2 Latin America Insulin Biosimilars Forecasted Market Size by Country
8.2.1 Latin America Insulin Biosimilars Sales in Volume by Country (2024-2034)
8.2.2 Latin America Insulin Biosimilars Sales in Value by Country (2024-2034)
9 Middle East and Africa Insulin Biosimilars by Country
9.1 Middle East and Africa Insulin Biosimilars Historic Market Size by Country
9.1.1 Middle East and Africa Insulin Biosimilars Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
9.1.2 Middle East and Africa Insulin Biosimilars Sales in Volume by Country (2024-2024)
9.1.3 Middle East and Africa Insulin Biosimilars Sales in Value by Country (2024-2024)
9.2 Middle East and Africa Insulin Biosimilars Forecasted Market Size by Country
9.2.1 Middle East and Africa Insulin Biosimilars Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Insulin Biosimilars Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Sanofi S.A.
10.1.1 Sanofi S.A. Company Information
10.1.2 Sanofi S.A. Introduction and Business Overview
10.1.3 Sanofi S.A. Insulin Biosimilars Sales, Revenue and Gross Margin (2024-2024)
10.1.4 Sanofi S.A. Insulin Biosimilars Products Offered
10.1.5 Sanofi S.A. Recent Development
10.2 Boehringer Ingelheim
10.2.1 Boehringer Ingelheim Company Information
10.2.2 Boehringer Ingelheim Introduction and Business Overview
10.2.3 Boehringer Ingelheim Insulin Biosimilars Sales, Revenue and Gross Margin (2024-2024)
10.2.4 Boehringer Ingelheim Insulin Biosimilars Products Offered
10.2.5 Boehringer Ingelheim Recent Development
10.3 Eli Lilly & Co.
10.3.1 Eli Lilly & Co. Company Information
10.3.2 Eli Lilly & Co. Introduction and Business Overview
10.3.3 Eli Lilly & Co. Insulin Biosimilars Sales, Revenue and Gross Margin (2024-2024)
10.3.4 Eli Lilly & Co. Insulin Biosimilars Products Offered
10.3.5 Eli Lilly & Co. Recent Development
10.4 Novo Nordisk A/S
10.4.1 Novo Nordisk A/S Company Information
10.4.2 Novo Nordisk A/S Introduction and Business Overview
10.4.3 Novo Nordisk A/S Insulin Biosimilars Sales, Revenue and Gross Margin (2024-2024)
10.4.4 Novo Nordisk A/S Insulin Biosimilars Products Offered
10.4.5 Novo Nordisk A/S Recent Development
10.5 Biocon
10.5.1 Biocon Company Information
10.5.2 Biocon Introduction and Business Overview
10.5.3 Biocon Insulin Biosimilars Sales, Revenue and Gross Margin (2024-2024)
10.5.4 Biocon Insulin Biosimilars Products Offered
10.5.5 Biocon Recent Development
10.6 Geropharm
10.6.1 Geropharm Company Information
10.6.2 Geropharm Introduction and Business Overview
10.6.3 Geropharm Insulin Biosimilars Sales, Revenue and Gross Margin (2024-2024)
10.6.4 Geropharm Insulin Biosimilars Products Offered
10.6.5 Geropharm Recent Development
10.7 Wockhardt
10.7.1 Wockhardt Company Information
10.7.2 Wockhardt Introduction and Business Overview
10.7.3 Wockhardt Insulin Biosimilars Sales, Revenue and Gross Margin (2024-2024)
10.7.4 Wockhardt Insulin Biosimilars Products Offered
10.7.5 Wockhardt Recent Development
10.8 Gan&Lee Pharmaceuticals
10.8.1 Gan&Lee Pharmaceuticals Company Information
10.8.2 Gan&Lee Pharmaceuticals Introduction and Business Overview
10.8.3 Gan&Lee Pharmaceuticals Insulin Biosimilars Sales, Revenue and Gross Margin (2024-2024)
10.8.4 Gan&Lee Pharmaceuticals Insulin Biosimilars Products Offered
10.8.5 Gan&Lee Pharmaceuticals Recent Development
10.9 The United Laboratories International
10.9.1 The United Laboratories International Company Information
10.9.2 The United Laboratories International Introduction and Business Overview
10.9.3 The United Laboratories International Insulin Biosimilars Sales, Revenue and Gross Margin (2024-2024)
10.9.4 The United Laboratories International Insulin Biosimilars Products Offered
10.9.5 The United Laboratories International Recent Development
10.10 Tonghua Dongbao Pharmaceutical
10.10.1 Tonghua Dongbao Pharmaceutical Company Information
10.10.2 Tonghua Dongbao Pharmaceutical Introduction and Business Overview
10.10.3 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales, Revenue and Gross Margin (2024-2024)
10.10.4 Tonghua Dongbao Pharmaceutical Insulin Biosimilars Products Offered
10.10.5 Tonghua Dongbao Pharmaceutical Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Insulin Biosimilars Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Insulin Biosimilars Industrial Chain Analysis
11.4 Insulin Biosimilars Market Dynamics
11.4.1 Insulin Biosimilars Industry Trends
11.4.2 Insulin Biosimilars Market Drivers
11.4.3 Insulin Biosimilars Market Challenges
11.4.4 Insulin Biosimilars Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Insulin Biosimilars Distributors
12.3 Insulin Biosimilars Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Rapid-Acting Biosimilars
Table 2. Major Company of Long-Acting Biosimilars
Table 3. Major Company of Premixed Biosimilars
Table 4. Global Insulin Biosimilars Sales by Type 2024 VS 2022 VS 2034 (US$ Million)
Table 5. Global Insulin Biosimilars Sales by Type (2024-2024) & (K Units)
Table 6. Global Insulin Biosimilars Sales Market Share in Volume by Type (2024-2024)
Table 7. Global Insulin Biosimilars Sales by Type (2024-2024) & (US& Million)
Table 8. Global Insulin Biosimilars Market Share in Value by Type (2024-2024)
Table 9. Global Insulin Biosimilars Price by Type (2024-2024) & (USD/Unit)
Table 10. Global Insulin Biosimilars Sales by Type (2024-2034) & (K Units)
Table 11. Global Insulin Biosimilars Sales Market Share in Volume by Type (2024-2034)
Table 12. Global Insulin Biosimilars Sales by Type (2024-2034) & (US$ Million)
Table 13. Global Insulin Biosimilars Sales Market Share in Value by Type (2024-2034)
Table 14. Global Insulin Biosimilars Price by Type (2024-2034) & (USD/Unit)
Table 15. North America Insulin Biosimilars Sales by Type (2024-2024) & (K Units)
Table 16. North America Insulin Biosimilars Sales by Type (2024-2024) & (US$ Million)
Table 17. Europe Insulin Biosimilars Sales (K Units) by Type (2024-2024)
Table 18. Europe Insulin Biosimilars Sales by Type (2024-2024) & (US$ Million)
Table 19. Asia-Pacific Insulin Biosimilars Sales (K Units) by Type (2024-2024)
Table 20. Asia-Pacific Insulin Biosimilars Sales by Type (2024-2024) & (US$ Million)
Table 21. Latin America Insulin Biosimilars Sales (K Units) by Type (2024-2024)
Table 22. Latin America Insulin Biosimilars Sales by Type (2024-2024) & (US$ Million)
Table 23. Middle East and Africa Insulin Biosimilars Sales (K Units) by Type (2024-2024)
Table 24. Middle East and Africa Insulin Biosimilars Sales by Type (2024-2024) & (US$ Million)
Table 25. Global Insulin Biosimilars Sales by Company (2024-2024) & (K Units)
Table 26. Global Insulin Biosimilars Sales Share by Company (2024-2024)
Table 27. Global Insulin Biosimilars Revenue by Company (2024-2024) & (US$ Million)
Table 28. Global Insulin Biosimilars Revenue Share by Company (2024-2024)
Table 29. Global Market Insulin Biosimilars Price by Company (2024-2024) & (USD/Unit)
Table 30. Global Insulin Biosimilars Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 31. Global Insulin Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 32. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Insulin Biosimilars as of 2022)
Table 33. Date of Key Manufacturers Enter into Insulin Biosimilars Market
Table 34. Key Manufacturers Insulin Biosimilars Product Type
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Insulin Biosimilars Market Size Comparison by Region (US$ Million): 2024 VS 2022 VS 2034
Table 37. Global Insulin Biosimilars Sales by Region (2024-2024) & (K Units)
Table 38. Global Insulin Biosimilars Sales Market Share in Volume by Region (2024-2024)
Table 39. Global Insulin Biosimilars Sales by Region (2024-2024) & (US$ Million)
Table 40. Global Insulin Biosimilars Sales Market Share in Value by Region (2024-2024)
Table 41. Global Insulin Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2024-2024)
Table 42. Global Insulin Biosimilars Sales by Region (2024-2034) & (K Units)
Table 43. Global Insulin Biosimilars Sales Market Share in Volume by Region (2024-2034)
Table 44. Global Insulin Biosimilars Sales by Region (2024-2034) & (US$ Million)
Table 45. Global Insulin Biosimilars Sales Market Share in Value by Region (2024-2034)
Table 46. Global Insulin Biosimilars Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2024-2034)
Table 47. Global Insulin Biosimilars Sales by Application: 2024 VS 2022 VS 2034 (US$ Million)
Table 48. Global Insulin Biosimilars Sales by Application (2024-2024) & (K Units)
Table 49. Global Insulin Biosimilars Sales Market Share in Volume by Application (2024-2024)
Table 50. Global Insulin Biosimilars Sales by Application (2024-2024) & (US$ Million)
Table 51. Global Insulin Biosimilars Sales Market Share in Value by Application (2024-2024)
Table 52. Global Insulin Biosimilars Price by Application (2024-2024) & (USD/Unit)
Table 53. Global Insulin Biosimilars Sales by Application (2024-2034) & (K Units)
Table 54. Global Insulin Biosimilars Sales Market Share in Volume by Application (2024-2034)
Table 55. Global Insulin Biosimilars Sales by Application (2024-2034) & (US$ Million)
Table 56. Global Insulin Biosimilars Sales Market Share in Value by Application (2024-2034)
Table 57. Global Insulin Biosimilars Price by Application (2024-2034) & (USD/Unit)
Table 58. North America Insulin Biosimilars Sales by Application (2024-2024) (K Units)
Table 59. North America Insulin Biosimilars Sales by Application (2024-2024) & (US$ Million)
Table 60. Europe Insulin Biosimilars Sales by Application (2024-2024) (K Units)
Table 61. Europe Insulin Biosimilars Sales by Application (2024-2024) & (US$ Million)
Table 62. Asia-Pacific Insulin Biosimilars Sales by Application (2024-2024) (K Units)
Table 63. Asia-Pacific Insulin Biosimilars Sales by Application (2024-2024) & (US$ Million)
Table 64. Latin America Insulin Biosimilars Sales by Application (2024-2024) (K Units)
Table 65. Latin America Insulin Biosimilars Sales by Application (2024-2024) & (US$ Million)
Table 66. Middle East and Africa Insulin Biosimilars Sales by Application (2024-2024) (K Units)
Table 67. Middle East and Africa Insulin Biosimilars Sales by Application (2024-2024) & (US$ Million)
Table 68. North America Insulin Biosimilars Sales by Country (2024-2024) & (K Units)
Table 69. North America Insulin Biosimilars Sales Market Share in Volume by Country (2024-2024)
Table 70. North America Insulin Biosimilars Sales by Country (2024-2024) & (US$ Million)
Table 71. North America Insulin Biosimilars Sales Market Share in Value by Country (2024-2024)
Table 72. North America Insulin Biosimilars Sales by Country (2024-2034) & (K Units)
Table 73. North America Insulin Biosimilars Sales Market Share in Volume by Country (2024-2034)
Table 74. North America Insulin Biosimilars Sales by Country (2024-2034) & (US$ Million)
Table 75. North America Insulin Biosimilars Sales Market Share in Value by Country (2024-2034)
Table 76. Europe Insulin Biosimilars Sales by Country (2024-2024) & (K Units)
Table 77. Europe Insulin Biosimilars Sales Market Share in Volume by Country (2024-2024)
Table 78. Europe Insulin Biosimilars Sales by Country (2024-2024) & (US$ Million)
Table 79. Europe Insulin Biosimilars Sales Market Share in Value by Country (2024-2024)
Table 80. Europe Insulin Biosimilars Sales by Country (2024-2034) & (K Units)
Table 81. Europe Insulin Biosimilars Sales Market Share in Volume by Country (2024-2034)
Table 82. Europe Insulin Biosimilars Sales by Country (2024-2034) & (US$ Million)
Table 83. Europe Insulin Biosimilars Sales Market Share in Value by Country (2024-2034)
Table 84. Asia-Pacific Insulin Biosimilars Sales by Region (2024-2024) & (K Units)
Table 85. Asia-Pacific Insulin Biosimilars Sales Market Share in Volume by Region (2024-2024)
Table 86. Asia-Pacific Insulin Biosimilars Sales by Region (2024-2024) & (US$ Million)
Table 87. Asia-Pacific Insulin Biosimilars Sales Market Share in Value by Region (2024-2024)
Table 88. Asia-Pacific Insulin Biosimilars Sales by Region (2024-2034) & (K Units)
Table 89. Asia-Pacific Insulin Biosimilars Sales Market Share in Volume by Region (2024-2034)
Table 90. Asia-Pacific Insulin Biosimilars Sales by Region (2024-2034) & (US$ Million)
Table 91. Asia-Pacific Insulin Biosimilars Sales Market Share in Value by Region (2024-2034)
Table 92. Latin America Insulin Biosimilars Sales by Country (2024-2024) & (K Units)
Table 93. Latin America Insulin Biosimilars Sales Market Share in Volume by Country (2024-2024)
Table 94. Latin America Insulin Biosimilars Sales by Country (2024-2024) & (US$ Million)
Table 95. Latin America Insulin Biosimilars Sales Market Share in Value by Country (2024-2024)
Table 96. Latin America Insulin Biosimilars Sales by Country (2024-2034) & (K Units)
Table 97. Latin America Insulin Biosimilars Sales Market Share in Volume by Country (2024-2034)
Table 98. Latin America Insulin Biosimilars Sales by Country (2024-2034) & (US$ Million)
Table 99. Latin America Insulin Biosimilars Sales Market Share in Value by Country (2024-2034)
Table 100. Middle East and Africa Insulin Biosimilars Sales by Country (2024-2024) & (K Units)
Table 101. Middle East and Africa Insulin Biosimilars Sales Market Share in Volume by Country (2024-2024)
Table 102. Middle East and Africa Insulin Biosimilars Sales by Country (2024-2024) & (US$ Million)
Table 103. Middle East and Africa Insulin Biosimilars Sales Market Share in Value by Country (2024-2024)
Table 104. Middle East and Africa Insulin Biosimilars Sales by Country (2024-2034) & (K Units)
Table 105. Middle East and Africa Insulin Biosimilars Sales Market Share in Volume by Country (2024-2034)
Table 106. Middle East and Africa Insulin Biosimilars Sales by Country (2024-2034) & (US$ Million)
Table 107. Middle East and Africa Insulin Biosimilars Sales Market Share in Value by Country (2024-2034)
Table 108. Sanofi S.A. Company Information
Table 109. Sanofi S.A. Introduction and Business Overview
Table 110. Sanofi S.A. Insulin Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 111. Sanofi S.A. Insulin Biosimilars Product
Table 112. Sanofi S.A. Recent Development
Table 113. Boehringer Ingelheim Company Information
Table 114. Boehringer Ingelheim Introduction and Business Overview
Table 115. Boehringer Ingelheim Insulin Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 116. Boehringer Ingelheim Insulin Biosimilars Product
Table 117. Boehringer Ingelheim Recent Development
Table 118. Eli Lilly & Co. Company Information
Table 119. Eli Lilly & Co. Introduction and Business Overview
Table 120. Eli Lilly & Co. Insulin Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 121. Eli Lilly & Co. Insulin Biosimilars Product
Table 122. Eli Lilly & Co. Recent Development
Table 123. Novo Nordisk A/S Company Information
Table 124. Novo Nordisk A/S Introduction and Business Overview
Table 125. Novo Nordisk A/S Insulin Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 126. Novo Nordisk A/S Insulin Biosimilars Product
Table 127. Novo Nordisk A/S Recent Development
Table 128. Biocon Company Information
Table 129. Biocon Introduction and Business Overview
Table 130. Biocon Insulin Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 131. Biocon Insulin Biosimilars Product
Table 132. Biocon Recent Development
Table 133. Geropharm Company Information
Table 134. Geropharm Introduction and Business Overview
Table 135. Geropharm Insulin Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 136. Geropharm Insulin Biosimilars Product
Table 137. Geropharm Recent Development
Table 138. Wockhardt Company Information
Table 139. Wockhardt Introduction and Business Overview
Table 140. Wockhardt Insulin Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 141. Wockhardt Insulin Biosimilars Product
Table 142. Wockhardt Recent Development
Table 143. Gan&Lee Pharmaceuticals Company Information
Table 144. Gan&Lee Pharmaceuticals Introduction and Business Overview
Table 145. Gan&Lee Pharmaceuticals Insulin Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 146. Gan&Lee Pharmaceuticals Insulin Biosimilars Product
Table 147. Gan&Lee Pharmaceuticals Recent Development
Table 148. The United Laboratories International Company Information
Table 149. The United Laboratories International Introduction and Business Overview
Table 150. The United Laboratories International Insulin Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 151. The United Laboratories International Insulin Biosimilars Product
Table 152. The United Laboratories International Recent Development
Table 153. Tonghua Dongbao Pharmaceutical Company Information
Table 154. Tonghua Dongbao Pharmaceutical Introduction and Business Overview
Table 155. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2024-2024)
Table 156. Tonghua Dongbao Pharmaceutical Insulin Biosimilars Product
Table 157. Tonghua Dongbao Pharmaceutical Recent Development
Table 158. Key Raw Materials Lists
Table 159. Raw Materials Key Suppliers Lists
Table 160. Insulin Biosimilars Market Trends
Table 161. Insulin Biosimilars Market Drivers
Table 162. Insulin Biosimilars Market Challenges
Table 163. Insulin Biosimilars Market Restraints
Table 164. Insulin Biosimilars Distributors List
Table 165. Insulin Biosimilars Downstream Customers
Table 166. Research Programs/Design for This Report
Table 167. Key Data Information from Secondary Sources
Table 168. Key Data Information from Primary Sources
List of Figures
Figure 1. Insulin Biosimilars Product Picture
Figure 2. Global Insulin Biosimilars Market Size, 2024 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Insulin Biosimilars Market Size Status and Outlook (2024-2034) & (US$ Million)
Figure 4. Global Insulin Biosimilars Sales Status and Outlook (2024-2034) & (K Units)
Figure 5. Product Picture of Rapid-Acting Biosimilars
Figure 6. Global Rapid-Acting Biosimilars Sales YoY Growth (2024-2034) & (K Units)
Figure 7. Product Picture of Long-Acting Biosimilars
Figure 8. Global Long-Acting Biosimilars Sales YoY Growth (2024-2034) & (K Units)
Figure 9. Product Picture of Premixed Biosimilars
Figure 10. Global Premixed Biosimilars Sales YoY Growth (2024-2034) & (K Units)
Figure 11. Global Insulin Biosimilars Sales by Type (2024-2034) & (US$ Million)
Figure 12. Global Insulin Biosimilars Sales Market Share by Type in 2022 & 2034
Figure 13. North America Insulin Biosimilars Sales Market Share in Volume by Type in 2022
Figure 14. North America Insulin Biosimilars Sales Market Share in Value by Type in 2022
Figure 15. Europe Insulin Biosimilars Sales Market Share in Volume by Type in 2022
Figure 16. Europe Insulin Biosimilars Sales Market Share in Value by Type in 2022
Figure 17. Asia-Pacific Insulin Biosimilars Sales Market Share in Volume by Type in 2022
Figure 18. Asia-Pacific Insulin Biosimilars Sales Market Share in Value by Type in 2022
Figure 19. Latin America Insulin Biosimilars Sales Market Share in Volume by Type in 2022
Figure 20. Latin America Insulin Biosimilars Sales Market Share in Value by Type in 2022
Figure 21. Middle East and Africa Insulin Biosimilars Sales Market Share in Volume by Type in 2022
Figure 22. Middle East and Africa Insulin Biosimilars Sales Market Share in Value by Type in 2022
Figure 23. The 5 and 10 Largest Manufacturers in the World: Market Share by Insulin Biosimilars Sales in 2022
Figure 24. The 5 and 10 Largest Manufacturers in the World: Market Share by Insulin Biosimilars Revenue in 2022
Figure 25. Insulin Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2024 VS 2022
Figure 26. Product Picture of Type I Diabetes
Figure 27. Global Type I Diabetes Sales YoY Growth (2024-2034) & (K Units)
Figure 28. Product Picture of Type II Diabetes
Figure 29. Global Type II Diabetes Sales YoY Growth (2024-2034) & (K Units)
Figure 30. Global Insulin Biosimilars Sales by Application (2024-2034) & (US$ Million)
Figure 31. Global Insulin Biosimilars Sales Market Share by Application in 2022 & 2034
Figure 32. North America Insulin Biosimilars Sales Market Share in Volume by Application in 2022
Figure 33. North America Insulin Biosimilars Sales Market Share in Value by Application in 2022
Figure 34. Europe Insulin Biosimilars Sales Market Share in Volume by Application in 2022
Figure 35. Europe Insulin Biosimilars Sales Market Share in Value by Application in 2022
Figure 36. Asia-Pacific Insulin Biosimilars Sales Market Share in Volume by Application in 2022
Figure 37. Asia-Pacific Insulin Biosimilars Sales Market Share in Value by Application in 2022
Figure 38. Latin America Insulin Biosimilars Sales Market Share in Volume by Application in 2022
Figure 39. Latin America Insulin Biosimilars Sales Market Share in Value by Application in 2022
Figure 40. Middle East and Africa Insulin Biosimilars Sales Market Share in Value by Application in 2022
Figure 41. Key Raw Materials Price
Figure 42. Insulin Biosimilars Manufacturing Cost Structure
Figure 43. Insulin Biosimilars Industrial Chain Analysis
Figure 44. Channels of Distribution
Figure 45. Distributors Profiles
Figure 46. Bottom-up and Top-down Approaches for This Report
Figure 47. Data Triangulation
Figure 48. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries